Altimmune (NASDAQ:ALT) Given "Market Perform" Rating at William Blair

William Blair reissued their market perform rating on shares of Altimmune (NASDAQ:ALT - Free Report) in a research note released on Friday morning,RTT News reports.

Other research analysts also recently issued reports about the company. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research note on Monday, March 3rd. Stifel Nicolaus assumed coverage on Altimmune in a research report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Altimmune has an average rating of "Moderate Buy" and a consensus price target of $20.83.

Altimmune Price Performance

Shares of NASDAQ ALT traded down $0.36 during mid-day trading on Friday, hitting $5.61. 2,528,672 shares of the stock traded hands, compared to its average volume of 3,009,963. Altimmune has a twelve month low of $5.14 and a twelve month high of $11.16. The company has a market cap of $432.05 million, a PE ratio of -3.62 and a beta of 0.87. The firm has a 50 day simple moving average of $6.45 and a two-hundred day simple moving average of $7.11.

Remove Ads

Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, equities research analysts anticipate that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On Altimmune

Several institutional investors have recently bought and sold shares of ALT. Larson Financial Group LLC bought a new position in shares of Altimmune in the third quarter worth $31,000. SBI Securities Co. Ltd. bought a new stake in Altimmune during the fourth quarter valued at $45,000. Virtus ETF Advisers LLC bought a new stake in Altimmune during the fourth quarter valued at $60,000. Cullen Frost Bankers Inc. bought a new stake in Altimmune during the fourth quarter valued at $72,000. Finally, 180 Wealth Advisors LLC purchased a new stake in Altimmune during the fourth quarter valued at about $78,000. Hedge funds and other institutional investors own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.